Are we closer to achieving precision medicine for migraine treatment? A narrative review

dc.authoridZhantleuova, Aisha/0009-0001-2879-5648
dc.authoridPark, Hong-Kyun/0000-0002-8120-2469
dc.authoridMavridis, Theodoros/0000-0002-5952-5106
dc.authoridCasillo, Francesco/0000-0003-4642-950X
dc.authoridGenc, Hamit/0000-0002-6198-2883
dc.authoridDahshan, Ahmed/0000-0002-0478-8486
dc.authoridLee, Wonwoo/0000-0002-0907-4212
dc.contributor.authorIhara, Keiko
dc.contributor.authorCasillo, Francesco
dc.contributor.authorDahshan, Ahmed
dc.contributor.authorGenc, Hamit
dc.contributor.authorJusupova, Asel
dc.contributor.authorKarbozova, Kunduz
dc.contributor.authorLee, Wonwoo
dc.date.accessioned2025-10-11T20:48:10Z
dc.date.available2025-10-11T20:48:10Z
dc.date.issued2024
dc.departmentDüzce Üniversitesien_US
dc.description.abstractBackground The term 'precision medicine' encompasses strategies to optimize diagnosis and outcome prediction and to tailor treatment for individual patients, in consideration of their unique characteristics. The greater availability of multifaceted datasets and strategies to model such data have made precision medicine increasingly possible in recent years. Precision medicine is especially needed in the migraine field since the response to migraine treatments is not universal amongst all individuals with migraine.Objective To provide a narrative review describing contributions to achieving precision medicine for migraine treatment.Methods A search of PubMed for English language articles of human participants published from 2005 to January 2024 was conducted to identify articles that reported research contributing to precision medicine for migraine treatment. The published literature was categorized and summarized according to the type of data that were included: clinical phenotypes, genomics, proteomics, physiologic measures, and brain imaging.Results Published studies have investigated characteristics associated with acute and preventive treatment responses, such as nonsteroidal anti-inflammatory drugs, triptans, onabotulinumtoxinA, and anti-calcitonin gene-related peptide monoclonal antibodies, in patients with episodic or chronic migraine. There is evidence that clinical, genetic, epigenetic, proteomic, physiologic, and brain imaging features might associate with migraine treatment outcomes, although inconsistencies for such findings clearly exist.Conclusions The published literature suggests that there are clinical and biological features which associate with, and might be useful for predicting, migraine treatment responses. To achieve precision medicine for migraine treatment, further research is needed that validates and expands on existing findings and tests the accuracy and value of migraine treatment prediction models in clinical settings.en_US
dc.identifier.doi10.1177/03331024241281518
dc.identifier.issn0333-1024
dc.identifier.issn1468-2982
dc.identifier.issue9en_US
dc.identifier.pmid39256924en_US
dc.identifier.scopus2-s2.0-85204035734en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1177/03331024241281518
dc.identifier.urihttps://hdl.handle.net/20.500.12684/21773
dc.identifier.volume44en_US
dc.identifier.wosWOS:001328346500003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofCephalalgiaen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectheadacheen_US
dc.subjectmigraineen_US
dc.subjectprecision medicineen_US
dc.subjectgenomicsen_US
dc.subjectproteomicsen_US
dc.subjectimagingen_US
dc.subjectpredictionen_US
dc.subjecttreatmenten_US
dc.subjectpersonalized medicineen_US
dc.titleAre we closer to achieving precision medicine for migraine treatment? A narrative reviewen_US
dc.typeReviewen_US

Dosyalar